Puma Biotech (PBYI) Reports Q3 EPS of $0.17

Puma Biotech (NASDAQ: PBYI) reported Q3 EPS of $0.17, versus ($1.36) reported last year. Revenue for the quarter came in at $62.6 million versus the consensus estimate of $57.94 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2